Dyno
Dyno Therapeutics is building high-performance genetic technologies solve the in vivo gene delivery challenge.
Challenge
How can we drive awareness of the need to solve gene therapy’s big delivery problem and position Dyno Therapeutics as the partner of choice for gene therapy developers looking to build better delivery methods, resulting in safer and more effective treatments?
Approach
The story is delivery.
Existing gene therapies have primarily used a small number of naturally occurring AAV vectors limited by low delivery efficiency as well as problems with pre-existing immunity and manufacturability.
To overcome these challenges, Dyno has pioneered the application of AI and high-throughput in vivo data collection to engineering AAV capsids for improved tissue targeting, immune-evasion and manufacturability. As a platform built to solve the most critical challenges facing gene therapy developers, Dyno’s industry-leading gene delivery solutions enable Dyno partners to create ever better gene therapies.
Thermal’s media strategy and relationships are increasing awareness of the Dyno brand, technology, and subsequent engagement with the company.
Impact
We have supported Dyno across several key milestones.
Most recently on October 24, 2024, Dyno announced a new strategic partnership potentially worth over $1B with Roche to advance AAV gene therapy vectors For neurological diseases.
We coordinated with Roche and issued this press release, secured an exclusive with Bloomberg, and coordinated an impactful day-of pitching strategy resulting in significant trade media coverage including Endpoints, Fierce Biotech, STAT, GEN, BioSpace, and other business coverage such as the Boston Business Journal.
“Our approach combines extensive in vivo data with the world’s most advanced AI models for sequence-function prediction, empowering Dyno capsid engineers with industry-leading capabilities for solving the longstanding challenge of therapeutic gene delivery. Dyno’s platform brings the entire field closer to realizing a future where all gene therapies are safe, effective, and widely accessible to all patients who need them.”
Eric Kelsic – CEO of Dyno Therapeutics
$1+BN
Roche partnership announced
#GeneTherapy
